Lineage Cell Therapeutics Inc. — Proxy Solicitation & Information Statement 2019

Jun 16, 2019

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [X] Filed by a Party other than the Registrant [ ]

Check the appropriate box:

[ ] Preliminary Proxy Statement

[ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

[ ] Definitive Proxy Statement

[X] Definitive Additional Materials

[ ] Soliciting Material Pursuant to §240.14a-12

BioTime, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

• [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  • (1) Title of each class of securities to which transaction applies:
  • (2) Aggregate number of securities to which transaction applies:
  • (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
  • (4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

• [ ] Fee paid previously with preliminary materials.
• [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
• (1) Amount previously paid:
• (2) Form, schedule or registration statement no.:
• (3) Filing party:
• (4) Date filed:

*** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on July 30, 2019

	Meeting Information
BIOTIME, INC.	Meeting Type: Annual Meeting
	For holders as of: June 10, 2019
	Date: July 30, 2019 Time: 7:30 AM PDT
	Location: BioTme Inc.
	1010 Atlantic Avenue
	Suite 102
	Alameda, CA 9450
1010 Atlantic Avenue Surce 102 Al aneda, CA 94501	This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side). We encourage you to access and review all of the important
	information contained in the proxy materials before voting. See the reverse side of this notice to obtain
	proxy materials and voting instructions.

Before You Vote

How to Access the Proxy Materials

How To Vote

Please Choose One of the Following Voting Methods

Vote In Person: Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting materials for any special requirements for meeting attendance. At the meeting you will need to request a ballot to vote these shares.

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow -> |xxxx xxxx xxxx xxxx xxxx | available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

Voting items The Board of Directors recommends you vote FOR the following nominees :
	1. Election of Directors Non inees
	1a. Deborah Androws 11. Alfred D. Kingslay	1b. Don Bailey 1g. Michael H. Mulroy	1c. Noal C. Bradsher 1h. Angus C. Russell	1d. Brian M. Culloy	10. Stephen C. Farrell

The Board of Directors recommends you vote FOR proposals 2, 3 and 4

1. To ratify the appointment of OUH & Co., LLP as the Company's independent registered public accounting firm for
   the fiscal year ending December 31, 2019

2. To approve, on an advisory basis, compensation paid to the Company's named executive officers

4 . To anond the Company's 2012 Equity Incentive Plan to increase the number of comon shares authorized for

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

0000425630_4 RI.0.1.18